<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1911234503
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ORATANE 20 mg Soft Capsules
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ISOTRETINOIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        61.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SWISS CAPS AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SWISS CAPS AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 467]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Thimar Aljazirah Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DOUGLAS MANUFACTURING Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        D10BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Oratane contains isotretinoin &ndash; a substance related to vitamin A, and one of a group of medicines called retinoids.<br /><strong>Oratane is used to treat severe forms of acne</strong> (such as nodular or conglobate acne, or acne that is at risk of causing permanent scarring) in adults and adolescents. You will use Oratane when your acne has not got better with anti-acne treatments, including antibiotics and skin treatments.<br />Oratane should not be used to treat prepubertal acne and not in children aged less than 12 years of age. Oratane treatment must be supervised by a dermatologist (a doctor specialized in the treatment of skin problems).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Oratane &hellip;<br />If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby.<br />If there is any chance you could become pregnant,</strong> you must follow the precautions under &ldquo;Pregnancy prevention programme&rdquo;, see section on &ldquo;Warnings and precautions&rdquo;.<br /><strong>If you are allergic to isotretinoin, peanut or soya or any other ingredients</strong> of this medicine (listed in section 6).<br /><strong>If your doctor has told you that you have intolerance</strong> to the sugars fructose or sorbitol.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <strong>If you have liver disease<br />If you have very high levels of blood fats</strong> (e.g. high cholesterol or triglycerides)<br /><strong>If you have very high levels of vitamin A</strong> in your body (hypervitaminosis A)<br /><strong>If you are receiving treatment with tetracyclines</strong> (a type of antibiotic) at the same time (see &ldquo;Other medicines and Oratane&rdquo;).</p><p dir="ltr"><strong>If any of these apply to you,</strong> go back to your doctor before taking any Oratane.</p><p dir="ltr"><strong>Warnings and Precautions&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong>Talk to your doctor or pharmacist before taking Oratane.</p><p dir="ltr"><strong>If you have ever had any kind of mental health problems. This includes depression, aggressive tendencies or mood changes. It also includes thoughts about hurting yourself or ending your life. This is because your mood may be affected while taking Oratane.</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Talk to your doctor if you experience persistent pain in your lower back or buttocks during treatment with Oratane. These symptoms may be signs of sacroiliitis, a type of inflammatory back pain. Your doctor may discontinue treatment with Oratane and refer you to a specialist for treatment of inflammatory back pain. Further evaluation may be needed including imaging modalities such as MRI.</p><p dir="ltr"><strong>Pregnancy prevention programme<br />Women who are pregnant must not take Oratane</strong>.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; This medicine can seriously harm an unborn baby (the medicine is said to be &lsquo;teratogenic&rsquo;) &ndash; it can cause serious abnormalities of the unborn baby&rsquo;s brain, face, ear, eye, heart and certain glands (thymus gland and parathyroid gland). It also makes a miscarriage more likely. This may happen even if Oratane is taken only for a short time during pregnancy.<br />&bull; You must not take Oratane if you are pregnant or if you think you might be pregnant.<br />&bull; You must not take Oratane if you are breastfeeding. The medicine is likely to pass into your milk and may harm your baby.<br />&bull; You must not take Oratane if you could get pregnant during treatment.<br />&bull; You must not get pregnant for one month after stopping this treatment because some medicine may still be left in your body.</p><p dir="ltr"><strong>Women who could get pregnant are prescribed Oratane under strict rules. This is because of the risk of serious harm to the unborn baby.</strong></p><p dir="ltr">These are the rules:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>&bull; Your doctor must explain the risk of harm to the unborn baby:</strong> you must understand why you must not get pregnant and what you need to do to prevent getting pregnant.<br /><strong>&bull; You must have discussed contraception (birth control) with your doctor.</strong> The doctor will give you information on how not to get pregnant. The doctor may refer you to a specialist for contraception advice.<br /><strong>&bull; Before you start treatment, your doctor will ask you to take a pregnancy test.</strong> The test must show that you are not pregnant (negative) when starting treatment with Oratane.<br /><strong>Women must use effective contraception before, during and after taking Oratane.<br />&bull; You must agree to use at least one very reliable method of contraception </strong>(for example an intra uterine device or contraceptive implant) or, two effective methods that work in different ways (for example a hormonal contraceptive pill and a condom). Discuss with your doctor which methods would be suitable for you.<br />&bull; You must use contraception for a month before taking Oratane, during treatment and for a month afterwards.<br />&bull; You must use contraception even if you do not have periods or you are not sexually active (unless your doctor decides this is not necessary).</p><p dir="ltr"><strong>Women must agree to pregnancy testing before, during and after taking Oratane<br />&bull; You must agree to regular follow-up visits, ideally every month.<br />&bull; You must agree to have regular pregnancy tests, ideally every month during treatment</strong> and, because some medicine may still be left in your body, 1 month after stopping Oratane (unless your doctor decides this is not necessary in your case).<br /><strong>&bull; You must agree to extra pregnancy tests if your doctor asks you.</strong><br />&bull; You must not get pregnant during treatment or for a month afterwards because some medicine may still be left in your body.<br /><strong>&bull; Your doctor will discuss all these points with you, using a checklist and will ask you (or a parent/guardian) to sign it.</strong> This form confirms that you have been told about the risks and that you will follow the rules above.</p><p dir="ltr"><strong>If you get pregnant while taking Oratane, stop taking the medicine straight away,</strong> and contact your doctor. Your doctor may refer you to a specialist for advice.</p><p dir="ltr">Also,<strong> if you become pregnant within one month after you stop taking Oratane,</strong> you should contact your doctor. Your doctor may send you to a specialist for advice.</p><p dir="ltr"><strong>Your doctor has written information on pregnancy prevention for the users of Oratane which should be given to you.</strong></p><p dir="ltr">A new prescription is needed for more treatment. Each prescription is only valid for 7 days.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Advice for men</strong><br />Oratane does not appear to damage sperm. Very low levels of isotretinoin are present in the semen of men taking Oratane, but too little to harm the unborn baby of your partner. You must remember not to share your medication with anyone, particularly not women.</p><p dir="ltr"><strong>Additional precautions<br />You should never give this medicinal product to another person. Please take any unused capsules to your pharmacist at the end of treatment.<br />You should not donate blood during treatment with this medicine and for 1 month after stopping Oratane because an unborn baby could be harmed if a pregnant patient receives your blood.</strong></p><p dir="ltr"><strong>Mental Health Problems</strong><br />You may not notice some changes in your mood and behavior and so it is very important that you tell your friends and family that you are taking this medicine. They may notice these changes and help you quickly identify any problems that you need to talk to your doctor about.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Advice for all patients<br />&bull; Tell your doctor if you have ever had any mental illness </strong>(including depression, suicidal behavior or psychosis), or if you take medicines for any of these conditions.<br /><strong>&bull; Severe Skin reactions</strong> (e.g. erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)) <strong>have been reported with the use of Oratane.</strong> The rash may progress to widespread blistering or peeling of the skin. You should also look for ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes).<br /><strong>&bull; Rarely, Oratane may cause severe allergic reactions </strong>some of which can affect skin in the form of eczema, hives and bruises or red patches on arms and legs. If you develop an allergic reaction, stop taking Oratane, seek urgent advice from a doctor and tell him that you are taking this medicine.<br /><strong>&bull; Cut down on intensive exercise and physical activity.</strong> Oratane can cause muscle and joint pain particularly in children and teenagers undertaking vigorous physical activity.<br /><strong>&bull; Oratane has been associated with inflammatory bowel disease</strong>. Your doctor will take you off<br />Oratane if you have severe bloody diarrhoea without any history of gastrointestinal disorders.<br /><strong>&bull; Oratane may cause dry eyes, intolerance to contact lenses and visual difficulties including decreased night vision.</strong> Cases of dry eyes not resolving after discontinuation of therapy have been reported. Tell your doctor if you have any of these symptoms. Your doctor may ask you to use lubricating eye ointment or tear replacement therapy. If you use contact lenses and you have developed intolerance to contact lenses, you may be advised to wear glasses during the treatment. Your doctor may refer you to a specialist for advice if you develop visual difficulties and you may be asked to stop taking Oratane.<br /><strong>&bull; Benign intracranial hypertension has been reported with Oratane use </strong>and in some cases where Oratane was used together with tetracyclines (a type of antibiotic). Stop taking Oratane and seek urgent advice from your doctor if you develop symptoms like headache, nausea, vomiting and visual disturbances. Your doctor may refer you to a specialist to check for swelling of optic disk in the eye (papilloedema).<br /><strong>&bull; Oratane may increase liver enzyme levels.</strong> Your doctor will do blood tests before, during and after Oratane treatment to check these levels. If they stay high, your doctor may lower your dose or take you off Oratane.<br /><strong>&bull; Oratane commonly increases blood fats, </strong>such as cholesterol or triglycerides. Your doctor will test these levels before, during and after Oratane treatment. It is best that you do not drink alcoholic drinks or that you at least reduce the amount you usually drink while on treatment. Tell your doctor if you already have high blood fats, diabetes (high blood sugars), are overweight, or an alcoholic. You may need blood tests more often. If your blood fats stay high, your doctor may lower your dose, or take you off Oratane.<br /><strong>&bull; Tell your doctor if you have any kidney problems.</strong> Your doctor may start you on a lower dose of Oratane and then increase it to the maximum tolerated dose.<br /><strong>&bull; Oratane may increase blood sugar levels.</strong> In rare cases, people become diabetic. Your doctor may monitor blood sugar levels during treatment, particularly if you already have diabetes, are overweight, or are an alcoholic.<br /><strong>&bull; Your skin is likely to get dry. </strong>Use a skin moisturising ointment or cream and a lip balm during treatment. To prevent skin irritation you should avoid using exfoliating or anti-acne products.<br /><strong>&bull; Avoid too much sun and do not use a sun-lamp or sun-bed. </strong>Your skin may become more sensitive to sunlight. Before you go out in the sun, use a sun-protection product with a high protection factor (SPF 15 or higher).<br /><strong>&bull; Don&rsquo;t have any cosmetic skin treatments. </strong>Oratane may make your skin more fragile. Don&rsquo;t have any waxing (hair removal), dermabrasion or laser treatments (removing horny skin or scars) during treatment, or for at least 6 months after treatment. They could cause scarring, skin irritation, or rarely, changes in the colour of your skin.</p><p dir="ltr"><strong>Children and adolescents</strong><br />The use of Oratane in children under the age of 12 is not recommended. This is because it is not known if it is safe or effective in this age group. Oratane should not be used to treat prepubertal acne and not in children aged less than 12 years of age.</p><p dir="ltr"><strong>Other medicines and Oratane</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including herbal and non-prescription products.<br /><strong>&bull; Do not take vitamin A supplements or tetracyclines </strong>(a type of antibiotic), or use any skin treatments for acne while you are on Oratane. It is fine to use moisturisers and emollients (skin creams or preparations that prevent water loss and have a softening effect on the skin).<br /><strong>&bull; Avoid the use of topical keratolytic or exfoliative anti-acne </strong>agents while you are on Oratane.</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p dir="ltr">For more information on contraception, pregnancy and breast-feeding, see section 2 &ldquo;Pregnancy prevention programme&rdquo;.</p><p dir="ltr"><strong>Driving and using machines</strong><br />You may not see as well at night during your treatment. This can happen suddenly. In rare cases this has continued after the treatment has stopped. Drowsiness and dizziness have been reported very rarely. If this happens to you, you should not drive or operate machinery.</p><p dir="ltr"><strong>Oratane contains sorbitol and soya-bean oil</strong><br />This medicine contains 7.58 mg sorbitol in each 10 mg capsule.<br />This medicine contains 24.26 mg sorbitol in each 20 mg capsule.<br />If you are allergic to peanut or soya, do not use this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take Oratane exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr"><strong>The usual starting dose</strong> is 0.5 mg per kilogram body weight per day (0.5 mg/kg/day).<br />So if you weigh 60 kg, your dose will usually start at 30 mg a day.<br /><strong>Take the capsules once or twice daily.</strong> Take on a full stomach. Swallow them whole, with a drink or a mouthful of food.<br /><strong>After a few weeks your doctor may adjust your dose. </strong>This depends on how you are getting on with your medicine. For most patients the dose will be between 0.5 and 1.0mg/kg/day. If you think that Oratane is too strong or too weak, talk to your doctor or pharmacist.<br /><strong>If you have severe kidney problems,</strong> you will usually start on a lower dose (such as 10 mg/day) which will be increased up to the highest dose your body can tolerate. If your body can&rsquo;t tolerate the recommended dose, you may be prescribed a lower dose: that can mean you are treated for longer and your acne might be more likely to come back.<br /><strong>A course of treatment usually lasts for 16 to 24 weeks.</strong> Most patients only need one course. Your acne may continue to improve for up to 8 weeks after treatment. You won&rsquo;t usually start another course until then.</p><p dir="ltr">Some people find their acne gets worse during the first weeks of treatment. It usually improves as treatment goes on.</p><p dir="ltr"><strong>If you take more Oratane capsules than you should</strong><br />If you take too many capsules or someone else accidentally takes your medicine, contact your doctor, pharmacist or nearest hospital immediately.<br /><strong>If you forget to take a dose</strong><br />If you miss a dose take it as soon as you can. However, if it is nearly time for your next dose, skip the missed dose and carry on as before. Do not take a double dose (two doses close together).</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor, or pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of the side effects associated with the use of isotretinoin are related to the dose. The side effects are generally reversible after changing the dose or stopping treatment, however some may continue after treatment has stopped. Some side effects can be serious and you must immediately contact your doctor.</p><p dir="ltr"><strong>Most serious side effects requiring immediate medical attention:<br />Mental problems<br />Rare effects </strong>(may affect up to 1 in every 1000 people)<br />Depression or related disorders. Signs of this include sad or empty mood, mood changes, anxiety, crying spells, irritability, loss of pleasure or interest in social or sports activities, sleeping too much or too little, changes in weight or appetite, school or work performance going down or trouble concentrating.<br />Existing depression getting worse.<br />Becoming violent or aggressive.<br /><strong>Very rare effects</strong> (may affect up to 1 in every 10,000 people)<br />Some people have had thoughts about hurting themselves or ending their own lives (suicidal thoughts), have tried to end their own lives (attempted suicide), or have ended their lives (suicide). These people may not appear to be depressed.<br />Unusual behavior.<br />Signs of psychosis: a loss of contact with reality, such as hearing voices or seeing things that are not there.</p><p dir="ltr"><strong>Contact your doctor straight away if you get signs of any of these mental problems</strong>.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Your doctor may tell you to stop taking Oratane. That may not be enough to stop the effects: you may need more help, and your doctor can arrange this.</p><p dir="ltr"><strong>Allergic reactions<br />Rare effects </strong>(may affect up to 1 in every 1000 people)<br />Serious (anaphylactic) reactions: difficulty breathing or swallowing caused by sudden swelling of the throat, face, lips and mouth. Also sudden swelling of the hands, feet and ankles.<br /><strong>Very rare effects </strong>(may effect up to 1 in every 10,000 people)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Sudden tight chest, shortness of breath and wheezing, particularly if you have asthma.<br /><strong>If you have a serious reaction, get emergency medical help immediately.</strong><br />If you have any allergic reaction, stop taking Oratane and contact your doctor.</p><p dir="ltr"><strong>Skin problems<br />Unknown frequency: (frequency cannot be estimated from the available data)</strong><br />Serious skin rashes (erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), which are potentially life-threatening and require immediate medical attention. These appear initially as circular patches often with central blisters usually on arms and hands or legs and feet, more severe rashes may include blistering of the chest and back. Additional symptoms such as infection of the eye (conjunctivitis) or ulcers of the mouth, throat or nose may occur. Severe forms of rash may progress to widespread peeling of the skin which can be life threatening. These serious skin rashes are often preceded by headache, fever, body aches (flu-like symptoms).</p><p dir="ltr"><strong>If you develop a serious rash or these skin symptoms, stop taking Oratane and contact your doctor immediately.<br />Liver and kidney problems<br />Very rare effects</strong> (may affect up to 1 in every 10,000 people)<br />Yellow skin or eyes, and feeling tired. These can be signs of hepatitis.<br /><strong>Stop taking Oratane straight away and contact your doctor.</strong><br />Difficulty urinating (passing water), swollen and puffy eyelids, feeling excessively tired.<br />These may be signs of kidney inflammation.<br /><strong>Stop taking Oratane straight away and contact your doctor.</strong></p><p dir="ltr"><strong>Nervous system problems<br />Very rare effects </strong>(may affect up to 1 in every 10,000 people)<br />Lasting headache, along with feeling sick (nausea), being sick (vomiting) and change in your eyesight including blurred vision. These may be signs of benign intracranial hypertension, especially if Oratane is taken with antibiotics called tetracycline.<br /><strong>Stop taking Oratane straight away and contact your doctor.</strong></p><p dir="ltr"><strong>Gut and stomach problems<br />Very rare effects</strong> (may affect up to 1 in every 10,000 people)<br />Severe abdominal (tummy) pain, with or without severe bloody diarrhea, feeling sick (nausea) and being sick (vomiting). These can be signs of serious gut conditions.<br /><strong>Stop taking Oratane straight away and contact your doctor.</strong></p><p dir="ltr"><strong>Eye disorders<br />Very rare effects</strong> (may affect up to 1 in every 10,000 people)<br />Blurred vision.</p><p dir="ltr"><strong>If you get blurred vision, stop taking Oratane straight away and contact your doctor.</strong><br /><strong>If</strong> your sight is affected in any other way tell a doctor as soon as you can.</p><p dir="ltr"><strong>Bones and muscles<br />Unknown frequency: (frequency cannot be estimated from the available data)</strong><br />Muscle weakness which can be potentially life threatening, may be associated with trouble moving arms or legs, painful, swollen, bruised areas of the body, dark coloured urine, reduced or no urine output, confusion or dehydration. These are signs of rhabdomyolysis, a breakdown of muscle tissue which can lead to kidney failure. This may occur if you are doing intensive physical activity while you&rsquo;re on Oratane.</p><p dir="ltr"><strong>Other side effects<br />Very common side effects with Oratane: </strong>(may affect more than 1 in 10 people)<br />Dryness of the skin, especially of the lips and face; inflamed skin, chapped and inflamed lips, rash, mild itching and slight peeling. Use a moisturising cream from the start of treatment.<br />Skin becomes more fragile and redder than usual, especially the face.<br />Back pain; muscle pain; joint pain particularly in children and teenagers.<br /><strong>To avoid making any bone or muscle problems worse, </strong>cut down on intensive physical activity while you&rsquo;re on Oratane.</p><p dir="ltr">Inflammation of the eye (conjunctivitis) and eyelid area; eyes feel dry and irritated. Ask a pharmacist for suitable eye drops. If you get dry eyes and wear contact lenses, you may need to wear glasses instead.Raised liver enzymes seen in blood tests.<br />Changed levels of fats in the blood (including HDL or triglycerides).<br />Bruising, bleeding or clotting more easily - if clotting cells are affected.<br />Anaemia &ndash; weakness, dizziness, pale skin &ndash; if red blood cells are affected.</p><p dir="ltr"><strong>Common side effects with Oratane</strong>: (may affect up to 1 in 10 people)<br />Headache.<br />Higher levels of cholesterol in the blood.<br />Protein or blood in the urine.<br />More liable to get infections - if the white blood cells are affected.<br />Inside of the nose becomes dry and crusted, causing mild nosebleeds.<br />Sore or inflamed throat and nose.<br />Allergic reactions such as rash, itchiness. If you have any allergic reaction, stop taking Oratane and contact your doctor.</p><p dir="ltr"><strong>Rare side effects with Oratane:</strong> (may affect up to 1 in 1,000 people)<br />Hair loss (alopecia). This is usually only temporary. Your hair should return to normal after the treatment ends.</p><p dir="ltr"><strong>Very rare side effects with Oratane:</strong> (may affect up to 1 in 10,000 people)<br />You may see less well at night; colour blindness and colour vision gets worse.<br />Sensitivity to light may increase; you may find that you need to wear sunglasses to protect your eyes from too bright sunlight. Other sight problems including distorted vision, cloudy surface on the eye (corneal opacity, cataracts). Excessive thirst; frequent need to urinate; blood tests show an increase in your blood sugar. These can all be signs of diabetes. Acne can get worse in the first few weeks, but symptoms should improve with time. Skin inflamed, swollen, and darker than usual, especially on the face. Excess sweating or itching. Arthritis; bone disorders (delayed growth, extra growth and changes to bone density); growing bones may stop growing. Calcium deposits in soft tissue, sore tendons, high levels of muscle breakdown products in your blood if you exercise vigorously. Bacterial infections at the base of the nail, changes to nails. Swellings, discharging, pus. Thickened scarring after surgery. Increased body hair. Convulsions, drowsiness, dizziness. Lymph glands may become swollen. Dry throat, hoarseness. Hearing difficulties. Generally feeling unwell. High levels of uric acid in the blood. Bacterial infections. Inflammation of the blood vessels (sometimes with bruising, red patches).</p><p dir="ltr"><strong>Unknown frequency: (frequency cannot be estimated from the available data)</strong><br />Dark or cola-coloured urine. Problems getting or maintaining an erection. Lower libido. Breast swelling with or without tenderness in males. Vaginal dryness. Sacroiliitis, a type of inflammatory back pain causing pain in your buttocks or lower back. Inflammation of the urethra.</p><p dir="ltr"><strong>Reporting Side Effects</strong><br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep out of the reach and sight of children.<br />Store Oratane 10 mg below 30 &deg;C<br />Store Oratane 20 mg below 30 &deg;C</p><p dir="ltr"><br />Store in the original package and keep blister in the outer carton in order to protect from moisture and light.</p><p dir="ltr">Do not use after the expiry date (EXP) stated on the pack and blister.<br />&nbsp;</p><p dir="ltr"><strong>Return left over capsules to your pharmacist. </strong>Only keep them if your doctor tells you to.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance</strong> in Oratane is Isotretinoin 10 mg and Isotretinoin 20 mg.<br /><strong>Other ingredients are </strong>Soya oil, DL-alpha-tocopherol, disodium edetate, butylated hydroxyanisole, partially hydrogenated soya oil, hydrogenated vegetable oil and yellow beeswax. The capsule shells contain: Gelatin, glycerol, sorbitol solution 70% (non-crystallising), titanium dioxide and purified water. The Oratane 10 mg also contains iron oxide black and ponceau 4R. The Oratane 20 mg capsule also contains ponceau 4R and indigotine lacquer.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Oratane 10 mg capsules are soft, oval, opaque light violet in color containing a yellow/orange liquid.
Oratane 20 mg capsules are soft, oval, opaque maroon-red in color containing a yellow/orange liquid.
Oratane 10 mg and 20 mg capsules are available in blister packs of 30 and 60 capsules. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Douglas Pharmaceuticals Ltd<br />Central Park Drive, Lincoln,<br />Auckland 0610,<br />New Zealand<br />Ph: (09) 835-0660<br />Email: medinfo@douglas.co.nz</p><p><strong>Manufacturer</strong><br />SWISS CAPS AG<br />Husenstrasse 35<br />CH-9533 Kirchberg<br />Switzerland</p><p><strong>To report any side effect(s) and quality problems, please contact the National Pharmacovigilance Center (NPC)</strong><br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/To report any side effect(s) and quality problems, please contact the National Pharmacovigilance Center (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي أوراتين على مادة ايزوتريتينوين - وهي مادة مرتبطة بفيتامين&nbsp;A ،وواحدة من مجموعة من الأدوية تسمى الرتينوئيدات.<br /><strong>يستخدم أوراتين لعلاج الأشكال الشديدة من حب الشباب</strong> (مثل حب الشباب المعقد وكروي الشكل ، أو حب الشباب المعرض لندوب دائمة) في البالغين والمراهقين. سوف تستخدم أوراتين إذا لم يكن هناك تحسن في بشرتك مع العلاجات المضادة لحب الشباب ، بما في ذلك المضادات الحيوية والعلاجات الجلدية.<br /><strong>لا ينبغي أن يستخدم أوراتين لعلاج حب الشباب قبل سن البلوغ وليس في الأطفال الذين تقل أعمارهم عن 12 سنة.<br />يجب أن يتم الإشراف على العلاج بأوراتين من قبل طبيب الأمراض الجلدية</strong> (طبيب متخصص في علاج مشاكل الجلد).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تأخذ أوراتين ...<br />&bull; إذا كنت حاملاً أو مرضعة ، تعتقدين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل.</strong><br /><strong>&bull; إذا كان هناك أي احتمال أن تصبحي حاملاً ،</strong> فعليك اتباع الاحتياطات الواردة في &ldquo;برنامج منع الحمل&rdquo; ، انظر قسم<br />&ldquo;التحذيرات والاحتياطات&rdquo;.<br /><strong>&bull; إذا كنت تعاني من حساسية تجاه ايزوتريتينوين أو الفول السوداني أو فول الصويا أو أي مكونات أخرى من هذا</strong><br />&nbsp;الدواء (مدرجة في القسم 6).<br />&bull; <strong>إذا أخبرك طبيبك أنك تعاني من عدم تحمل</strong> سكر الفواكه أو السوربيتول.<br />&bull; <strong>إذا كان لديك مرض الكبد<br />&bull; إذا كان لديك مستويات عالية جدًا من دهون الدم </strong>(على سبيل المثال ارتفاع نسبة الكوليسترول أو الدهون الثلاثية)<br /><strong>&bull; إذا كان لديك مستويات عالية جدًا من فيتامين (أ)</strong>في جسمك (فرط الفيتامين A)<br /><strong>&bull; إذا كنت تتلقى علاجًا باستخدام التتراسيكلين</strong> (نوع من المضادات الحيوية) في نفس الوقت (انظر &ldquo;الأدوية الأخرى والأوراتين&rdquo;)<br /><strong>&bull; إذا كانت أي من هذه الحالات تنطبق عليك ،</strong> عد إلى طبيبك قبل أخذ أوراتين.</p><p><strong>التحذيرات والاحتياطات</strong><br />تحدث إلى طبيبك أو الصيدلي قبل تناول أوراتين.</p><p><br /><strong>&bull; إذا كنت تعاني من أي نوع من مشاكل الصحة العقلية. وهذا يشمل الاكتئاب والميول العدوانية أو تغيرات المزاج.<br />يتضمن أيضًا أفكارًا حول إيذاء نفسك أو إنهاء حياتك. هذا لأن مزاجك قد يتأثر أثناء تناول أوراتين.</strong><br />تحدث إلى طبيبك إذا كنت تعاني من ألم مستمر في أسفل الظهر أو الأرداف أثناء العلاج باستخدام أوراتين. قد تكون<br />هذه الأعراض علامات على التهاب المفصل العجزي الحرقفي ، وهو نوع من آلام الظهر الالتهابية. قد يوقف طبيبك<br />العلاج باستخدام أوراتين ويحيلك إلى أخصائي لعلاج آلام الظهر الالتهابية. قد تكون هناك حاجة لمزيد من التقييم بما<br />في ذلك أساليب التصوير مثل التصوير بالرنين المغناطيسي.</p><p><br /><strong>برنامج منع الحمل<br />يجب على النساء الحوامل عدم تناول عقار أوراتين</strong><br />يمكن أن يؤذي هذا الدواء الجنين بشكل خطير )يقال إن الدواء &ldquo;مسبب للتشوه&rdquo;( - يمكن أن يسبب تشوهات خطيرة في دماغ الجنين والوجه والأذن والعين والقلب وبعض الغدد )الغدة الزعترية والغدة جار درقية(. كما أنه يزيد من احتمالية حدوث الإجهاض. قد يحدث هذا حتى إذا تم تناول أوراتين لفترة قصيرة فقط أثناء الحمل.<br />&bull; ممنوع تناول عقار أوراتين إذا كنت حاملا أو تعتقدين بأنك حامل.<br />&bull; ممنوع تناول أوراتين إذا كنت مرضعة. من المحتمل أن ينتقل الدواء إلى حليب الأم وقد يؤذي طفلك.<br />&bull; لا يجوز تناول أوراتين إذا كنت تستطيعين الحمل أثناء العلاج.<br />&bull; يجب ألا تحملي لمدة شهر بعد التوقف عن هذا العلاج لأن بعض الأدوية قد تبقى في جسمك.</p><p><br /><strong>يتم وصف أوراتين للنساء اللائي يمكن أن يحملن بموجب قواعد صارمة. هذا بسبب خطر حدوث ضرر جسيم للجنين</strong></p><p><br />هذه هي القواعد:<br /><strong>&bull; يجب على طبيبك أن يشرح مخاطر حدوث ضرر للجنين: </strong>يجب أن تفهمي لماذا لا يجب أن تحملي وما عليك القيام به لمنع الحمل.<br /><strong>&bull; يجب أن تناقشي وسائل منع الحمل (تحديد النسل) مع طبيبك</strong>. سيعطيك الطبيب معلومات عن كيفية عدم حدوث الحمل.<br />قد يحيلك الطبيب إلى أخصائي للحصول على المشورة بشأن منع الحمل.<br /><strong>&bull; قبل بدء العلاج سيطلب منك طبيبك إجراء اختبار الحمل.</strong> يجب أن يظهر الاختبار أنك لست حاملاً )سلبيًا( عند بدء<br />العلاج بأوراتين.</p><p><br /><strong>يجب على النساء استخدام وسائل منع الحمل الفعالة قبل وأثناء وبعد تناول أوراتين.</strong><br /><strong>&bull; يجب أن توافق على استخدام وسيلة واحدة على الأقل موثوقة للغاية لمنع الحمل</strong> (على سبيل المثال جهاز داخل<br />الرحم أو غرسة منع الحمل) <strong>أو طريقتين فعالتين تعملان بطرق مختلفة </strong>(على سبيل المثال ، حبوب منع الحمل<br />الهرمونية والواقي الذكري). ناقش مع طبيبك الطرق المناسبة لك.<br />&bull; يجب استخدام وسائل منع الحمل لمدة شهر قبل تناول أوراتين وخلال فترة العلاج ولمدة شهر بعد ذلك.<br />&bull; يجب عليك استخدام وسائل منع الحمل حتى لو انقطعت الدورة الشهرية أو كنت غير نشطة جنسيا(إلا إذا قرر طبيبك<br />أن هذا ليس ضروريا).</p><p>&nbsp;</p><p><strong>يجب أن توافق النساء على اختبار الحمل قبل وأثناء وبعد تناول عقار أوراتين.<br />&bull; يجب أن توافق على زيارات متابعة منتظمة ، ويفضل كل شهر.<br />&bull; يجب أن توافق على إجراء اختبارات حمل منتظمة ، من الناحية المثالية كل شهر أثناء العلاج </strong>، ولأن بعض الأدوية<br />قد تبقى في جسمك ، شهر واحد بعد إيقاف أوراتين (ما لم يقرر طبيبك أن هذا غير ضروري في حالتك).<br /><strong>&bull; يجب أن توافق على إجراء اختبارات حمل إضافية إذا طلب منك طبيبك ذلك.</strong><br />&bull; يجب ألا تحملي أثناء العلاج أو لمدة شهر بعد ذلك لأن بعض الأدوية قد تبقى في جسمك.<br /><strong>&bull; سيناقش طبيبك كل هذه النقاط معك ، مستخدماً قائمة مرجعية وسيطلب منك (أو أحد الوالدين / الوصي) التوقيع عليها.</strong><br />يؤكد هذا النموذج أنه قد تم إخبارك بالمخاطر وأنك ستتبع القواعد المذكورة أعلاه.</p><p><br /><strong>إذا حملت أثناء تناول أوراتين ، فتوقفي عن تناول الدواء على الفور واتصلي بطبيبك.</strong> قد يحيلك طبيبك إلى أخصائي للحصول على المشورة.</p><p><br />أيضًا ، إ<strong>ذا أصبحت حاملا في غضون شهر واحد بعد التوقف عن تناول أوراتين ،</strong> يجب عليك الاتصال بطبيبك. قد يرسلك طبيبك إلى أخصائي للحصول على المشورة.</p><p><br /><strong>كتب طبيبك معلومات حول منع الحمل لمستخدمي أوراتين والتي يجب أن تعطى لك.</strong></p><p><br />هناك حاجة إلى وصفة طبية جديدة لمزيد من العلاج. كل وصفة طبية صالحة لمدة 7 أيام فقط.</p><p><br /><strong>نصيحة للرجال</strong><br />لا يبدو أن أوراتين يدمر الحيوانات المنوية .توجد مستويات منخفضة جدا من الايزوتريتينوين في السائل المنوي للرجال الذين يتناولون أوراتين ، ولكن القليل جدا لإيذاء الطفل الذي لم يولد بعد من شريك حياتك. يجب عليك أن تتذكر أن لا تشارك الدواء الخاص بك مع أي شخص ، لا سيما النساء.</p><p><br /><strong>احتياطات إضافية<br />لا يجب أبدًا إعطاء هذا المنتج الدوائي لشخص آخر. يرجى أخذ أي كبسولات غير مستخدمة إلى الصيدلي في نهاية العلاج.<br />يجب عدم التبرع بالدم أثناء العلاج بهذا الدواء ولمدة شهر واحد بعد إيقاف أوراتين لأن الجنين قد يتضرر إذا تلقت المريضة<br />الحامل دمك.</strong></p><p><br /><strong>أمراض الصحة العقلية</strong><br />قد لا تلاحظ بعض التغييرات في حالتك المزاجية وسلوكك ولذلك من المهم جدًا أن تخبر أصدقائك وعائلتك أنك تتناول هذا الدواء. قد يلاحظون هذه التغييرات ويساعدونك في التعرف بسرعة على أي مشاكل تحتاج إلى التحدث مع طبيبك بشأنها.</p><p><br /><strong>نصيحة لجميع المرضى<br />&bull; أخبر طبيبك إذا كنت تعاني من أي مرض عقلي </strong>(بما في ذلك الاكتئاب أو السلوك الانتحاري أو الذهان) ، أو إذا كنت تتناول أدوية لأي من هذه الحالات.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>تفاعلات جلدية شديدة </strong>(مثل الحمامي عديدة الأشكال&nbsp;(EM)&nbsp;ومتلازمة ستيفنز جونسون (SJS)&nbsp;وانحلال البشرة&nbsp;النخري السمي (TEN)&nbsp;<strong>قد تم الإبلاغ عنها مع استخدام أوراتين.</strong> قد يتطور الطفح الجلدي إلى ظهور تقرحات&nbsp; أو تقشر الجلد. يجب عليك أيضًا البحث عن تقرحات في الفم والحلق والأنف والأعضاء التناسلية والتهاب الملتحمة(عيون حمراء ومنتفخة).<br /><strong>&bull; نادرا ، قد يسبب أوراتين ردود فعل تحسسية شديدة </strong>يمكن أن يؤثر بعضها على الجلد على شكل أكزيما وخلايا وكدمات أو بقع حمراء على الذراعين والساقين. إذا أصبت برد فعل تحسسي ، توقف عن تناول أوراتين ، واطلب المشورة العاجلة من الطبيب وأخبره أنك تتناول هذا الدواء.<br /><strong>&bull; قلل من التمارين المكثفة والنشاط البدني.</strong> يمكن أن يسبب أوراتين آلامًا في العضلات والمفاصل خاصة عند الأطفال والمراهقين الذين يمارسون نشاطًا بدنيًا قويًا.<br /><strong>&bull; ارتبط أوراتين بمرض التهاب الأمعاء. </strong>سيوقف طبيبك استخدامك للأوراتين إذا كنت تعاني من إسهال دموي حاد دون أي تاريخ من اضطرابات الجهاز الهضمي.<br /><strong>&bull; قد يسبب الأوراتين جفاف العين وعدم تحمل العدسات اللاصقة وصعوبات في الرؤية بما في ذلك ضعف الرؤية الليلية.</strong> تم الإبلاغ عن حالات جفاف العين التي لم يتم حلها بعد التوقف عن العلاج. أخبر طبيبك إذا كان لديك أي من هذه الأعراض. قد يطلب منك طبيبك استخدام مرهم العين المرطب أو العلاج ببدائل الدموع. إذا كنت تستخدم العدسات اللاصقة وتطور عدم تحمل العدسات اللاصقة ، فقد يُنصح بارتداء النظارات أثناء العلاج. قد يحيلك طبيبك إلى أخصائي للحصول على المشورة إذا كنت تعاني من صعوبات بصرية وقد يُطلب منك التوقف عن تناول أوراتين.<br /><strong>&bull; تم الإبلاغ عن ارتفاع ضغط الدم الحميد داخل الجمجمة باستخدام أوراتين</strong> وفي بعض الحالات حيث تم استخدام أوراتين مع التتراسيكلين )نوع من المضادات الحيوية(. توقف عن تناول أوراتين واطلب المشورة العاجلة من طبيبك إذا ظهرت عليك أعراض مثل الصداع والغثيان والقيء والاضطرابات البصرية. قد يحيلك طبيبك إلى أخصائي لفحص تورم القرص البصري في العين (الوذمة الحليمية).<br /><strong>&bull; قد يزيد الأوراتين من مستويات إنزيمات الكبد. </strong>سيقوم طبيبك بإجراء فحوصات الدم قبل وأثناء وبعد علاج أوراتين للتحقق من هذه المستويات. إذا بقيت مرتفعة ، قد يخفض طبيبك جرعتك أو يوقفك من استخدام أوراتين.<br /><strong>&bull; يزيد الأوراتين عادة من نسبة الدهون في الدم ، </strong>مثل الكوليسترول أو الدهون الثلاثية. سيختبر طبيبك هذه المستويات قبل وأثناء وبعد علاج أوراتين. من الأفضل ألا تشرب المشروبات الكحولية أو أن تقلل على الأقل الكمية التي تشربها عادة أثناء العلاج. أخبر طبيبك إذا كان لديك بالفعل ارتفاع في نسبة الدهون في الدم ، أو مرض السكري )ارتفاع نسبة السكر في الدم( ، أو زيادة الوزن ، أو إدمان الكحول. قد تحتاج إلى اختبارات الدم في كثير من الأحيان. إذا بقيت نسبة الدهون في دمك مرتفعة ، فقد يخفض طبيبك جرعتك ، أو يوقفك من استخدام أوراتين.<br /><strong>&bull; أخبر طبيبك إذا كان لديك أي مشاكل في الكلى.</strong> قد يبدأ طبيبك بجرعة أقل من أوراتين ثم يزيدها إلى الحد الأقصى للجرعة التي يمكن تحملها.<br /><strong>&bull; قد يزيد أوراتين من مستويات السكر في الدم. </strong>في حالات نادرة ، يصاب الناس بمرض السكري. قد يقوم طبيبك بمراقبة مستويات السكر في الدم أثناء العلاج ، خاصةً إذا كنت تعاني بالفعل من مرض السكري ، أو زيادة الوزن ، أو مدمن على الكحول.<br /><strong>&bull; من المحتمل أن تجف بشرتك.</strong> استخدم مرهم أو كريم مرطب للجلد ومرطب للشفاه أثناء العلاج. لمنع تهيج الجلد يجب تجنب استخدام منتجات التقشير أو المضادة لحب الشباب.<br /><strong>&bull; تجنب التعرض لأشعة الشمس الزائدة ولا تستخدم المصباح الشمسي أو سرير التشمس.</strong> قد تصبح بشرتك أكثر حساسية أو أعلى(. SPF لأشعة الشمس. قبل الخروج في الشمس ، استخدم منتجًا واقٍ من الشمس مع عامل حماية عالي ) 15<br />&bull; لا تستعمل أي علاجات تجميلية للبشرة. قد يجعل أوراتين بشرتك أكثر هشاشة. لا تستخدمي أي شمع (إزالة الشعر) أو سنفرة الجلد أو علاجات الليزر(إزالة الجلد المتقرن أو الندبات) أثناء العلاج ، أو لمدة 6 أشهر على الأقل بعد العلاج.<br />يمكن أن تسبب ندبات ، تهيج الجلد ، أو نادرا ، تغيرات في لون بشرتك.</p><p><strong>الأطفال والمراهقون</strong><br />لا ينصح باستخدام أوراتين في الأطفال دون سن 12 عامًا. هذا لأنه من غير المعروف ما إذا كانت آمنة أم فعالة في<br />هذه الفئة العمرية. لا ينبغي أن يستخدم أوراتين لعلاج حب الشباب قبل سن البلوغ وليس في الأطفال الذين تقل أعمارهم<br />عن 12 سنة.</p><p><strong>أدوية أخرى وأوراتين</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى بما في ذلك المنتجات العشبية<br />والمنتجات غير الموصوفة.</p><p><strong>&bull; لا تتناول مكملات فيتامين أ أو التتراسيكلين</strong> (نوع من المضادات الحيوية) ، أو تستخدم أي علاجات جلدية لحب الشباب أثناء استخدامك أوراتين. لا بأس من استخدام المرطبات والمطريات (كريمات البشرة أو المستحضرات التي تمنع فقدان الماء ولها تأثير ملين على الجلد).<br /><strong>&bull; تجنبي استخدام العلاجات الموضعية المزيلة للطبقة القرنية أو المضادّة لحبّ الشباب</strong> أثناء تناولك لأوراتين.</p><p><strong>الحمل والرضاعة</strong><br />إذا كنت حاملاً أو مرضعة ، تعتقدين أنك حامل أو تخططين لإنجاب طفل ، اسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء.</p><p><br />لمزيد من المعلومات حول وسائل منع الحمل، والحمل والرضاعة الطبيعية ، أنظري القسم 2 &ldquo;برنامج منع الحمل&rdquo;.</p><p><strong>القيادة واستعمال الآلات</strong><br />قد لا ترى جيدًا في الليل أثناء علاجك. يمكن أن يحدث هذا فجأة. في حالات نادرة ، استمر هذا بعد توقف العلاج. تم<br />الإبلاغ عن النعاس والدوخة في حالات نادرة جدًا. إذا حدث هذا لك ، فلا يجوز لك القيادة أو تشغيل الآلات.</p><p><strong>يحتوي أوراتين على السوربيتول وزيت فول الصويا</strong><br />يحتوي هذا الدواء على 7.58 ملجم سوربيتول في كل كبسولة 10 ملجم.<br />يحتوي هذا الدواء على 24.26 ملجم سوربيتول في كل كبسولة 20 ملجم.<br />إذا كنت تعاني من حساسية تجاه الفول السوداني أو فول الصويا ، فلا تستخدم هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>خذ دائمًا أوراتين تمامًا كما أخبرك طبيبك .استشر طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p><br /><strong>تبلغ جرعة البدء المعتادة </strong>0.5 ملجم لكل كيلوغرام من وزن الجسم يومياً ( 0.5 ملجم / كغ / يوم ). لذا ، إذا كان وزنك 60 كيلوجرامًا ، فستبدأ الجرعة بمعدل 30 ملجم يوميًا.<br /><strong>خذ الكبسولات مرة أو مرتين يومياً.</strong> خذ على معدة ممتلئة .ابتلعها كاملة ، مع شراب أو جرعة من الطعام.<br /><strong>بعد بضعة أسابيع قد يقوم الطبيب بتعديل الجرعة .</strong>هذا يعتمد على مدى تجاوب جسمك مع العلاج . بالنسبة لمعظم المرضى ، ستكون الجرعة بين 0.5 و 1.0 ملجم / كغ / يوم. إذا كنت تعتقد أن أوراتين له تأثير قوي جدًا أو ضعيف&nbsp;جدًا ، تحدث إلى طبيبك أو الصيدلي.<br /><strong>إذا كنت تعاني من مشاكل شديدة في الكلى ،</strong> فستبدأ عادةً بجرعة أقل )مثل 10 ملجم / يوم( والتي ستزداد إلى أعلى جرعة يمكن أن يتحملها جسمك .إذا كان جسدك لا يتحمل الجرعة الموصى بها ، فقد يتم وصف جرعة أقل لك :وهذا قد يعني أنك تعالج لفترة أطول ومن المرجح أن يعود ظهور حب الشباب لك.<br /><strong>مدة العلاج عادة ما تستمر لمدة 16 إلى 24 أسبوعًا</strong> .معظم المرضى يحتاجون إلى فترة علاج واحدة فقط .قد يستمر حب الشباب في التحسن لمدة تصل إلى 8 أسابيع بعد العلاج .لن تبدأ فترة علاج أخرى عادة حتى ذلك الحين.</p><p>بعض الناس يجدون أن حب الشباب يزداد سوءًا خلال الأسابيع الأولى من العلاج .عادة ما يتحسن مع استمرار العلاج.<br /><strong>إذا كنت تأخذ كبسولات أوراتين أكثر مما ينبغي</strong><br />إذا كنت تأخذ الكثير من الكبسولات أو إذا أخذ أي شخص آخر الدواء عن طريق الخطأ ، اتصل بطبيبك أو الصيدلي أو أقرب مستشفى على الفور.<br /><strong>إذا نسيت أن تأخذ الجرعة</strong><br />إذا نسيت أخذ جرعة فقم بأخذها في أقرب وقت ممكن .ومع ذلك ، إذا كان الوقت قد تخطى للجرعة التالية ، تخطى<br />الجرعة الفائتة واستمر في أخذ العلاج كما كان من قبل .لا تأخذ جرعة مضاعفة )جرعتان قريبتان من بعضهما البعض(.</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي أو الممرض /ة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع. ترتبط بعض الآثار الجانبية المرتبطة باستخدام الايزوتريتينوين بالجرعة. يمكن عكس الآثار الجانبية بشكل عام بعد تغيير الجرعة أو إيقاف العلاج ، ولكن قد يستمر بعضها بعد توقف العلاج. قد تكون بعض الآثار الجانبية خطيرة ويجب عليك الاتصال بطبيبك على الفور.</p><p><br /><strong>الآثار الجانبية الخطيرة التي تتطلب عناية طبية فورية :</strong><br /><strong>مشاكل عقلية<br />تأثيرات نادرة </strong>(قد تؤثر على 1 من كل 1000 شخص)<br />الاكتئاب أو الاضطرابات ذات الصلة .وتشمل الشعور بحالة مزاجية أو فارغة ، أو تغيرات في المزاج ، أو القلق ، أو نوبات البكاء ، أو التهيج ، أو فقدان المتعة ، أو الاهتمام بالأنشطة الاجتماعية أو الرياضية ، أو النوم أكثر من اللازم ، أو القليل جدًا ، أو تغيرات في الوزن أو الشهية ، أو انخفاض أداء المدرسة أو العمل أو صعوبة في التركيز.<br />إذا كنت تعاني من الإكتئاب قبل أخذ العلاج قد تزداد حالتك سوءا بعد بدء العلاج. تصبح الحالة عنيفة و عدوانية.<br /><strong>تأثيرات نادرة جدا </strong>(قد تؤثر على 1 من كل 10,000 شخص)<br />بعض الناس لديهم أفكار حول إيذاء أنفسهم أو إنهاء حياتهم (أفكار إنتحارية)، حاولوا إنهاء حياتهم )محاولة الانتحار( ،<br />أو أنهوا حياتهم (الانتحار) قد لا يبدو هؤلاء الناس مكتئبين.<br />سلوك غير عادي.<br />علامات الذهان: فقدان الاتصال مع الواقع ، مثل سماع الأصوات أو رؤية الأشياء غير الموجودة.</p><p><br /><strong>اتصل بطبيبك على الفور إذا ظهرت عليك علامات على أي من هذه المشاكل العقلية.</strong> قد يطلب منك طبيبك التوقف عن تناول أوراتين. قد لا يكون ذلك كافيًا لإيقاف التأثيرات :قد تحتاج إلى مزيد من المساعدة ، ويمكن لطبيبك ترتيب ذلك.</p><p>&nbsp;</p><p><strong>ردود الفعل التحسسية</strong><br />تأثيرات نادرة (قد تؤثر على 1 من كل 1000 شخص)<br />تفاعلات خطيرة(التأق أو صدمة حساسية): صعوبة في التنفس أو البلع بسبب التورم المفاجئ للحلق والوجه والشفتين والفم. أيضا تورم مفاجئ في اليدين والقدمين والكاحلين.<br /><strong>تأثيرات نادرة جدًا</strong> (قد تؤثر على 1 من كل 10,000 شخص)<br />ضيق مفاجئ في الصدر، ضيق في التنفس والصفير ، وخاصة إذا كان لديك الربو.<br /><strong>إذا كان لديك رد فعل تحسسي خطير ، احصل على مساعدة طبية طارئة على الفور.</strong><br />إذا كان لديك أي رد فعل تحسسي ، توقف عن أخذ أوراتين والاتصال بطبيبك</p><p>&nbsp;</p><p><strong>مشاكل الجلد<br />تكرار غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة)</strong><br />طفح جلدي خطير (حمامي متعددة الأشكال ، متلازمة ستيفنز جونسون ، انحلال البشرة السمي)، والتي يمكن أن تهدد الحياة وتتطلب عناية طبية فورية .تظهر هذه البقع في البداية على شكل بقع دائرية غالباً ما تكون بثور مركزية عادةً على الأذرع والأيدي أو الأرجل والقدمين ، وقد يشمل الطفح الجلدي الشديد ظهور تقرحات في الصدر والظهر. قد تحدث أعراض إضافية مثل عدوى العين )التهاب الملتحمة( أو قرحة الفم أو الحلق أو الأنف .قد تتطور الأشكال الحادة من الطفح الجلدي إلى تقشير واسع للجلد يمكن أن يهدد الحياة .هذه الطفح الجلدي الخطير غالباً ما يسبقه الصداع والحمى وآلام الجسم (أعراض تشبه أعراض الأنفلونزا).</p><p><strong>إذا أصبت بطفح جلدي خطير أو هذه الأعراض الجلدية ، توقف عن تناول أوراتين واتصل بطبيبك على الفور.<br />مشاكل الكبد والكلى<br />تأثيرات نادرة جدا </strong>(قد تؤثر على 1 من كل 10,000 أشخاص)<br />إصفرارالجلد أو العينين ، والشعور بالتعب. يمكن أن تكون هذه الأعراض مؤشرات على إلتهاب الكبد.<br /><strong>توقف عن أخذ أوراتين على الفور واتصل بطبيبك</strong>.<br />صعوبة في التبول (مرور الماء) ، تورم و إنتفاخ الجفنين، والشعور بالتعب المفرط .يمكن أن تكون هذه الأعراض مؤشرات على إلتهاب الكلى.<br /><strong>توقف عن أخذ أوراتين على الفور واتصل بطبيبك.</strong></p><p>&nbsp;</p><p><strong>مشاكل الجهاز العصبي<br />تأثيرات نادرة جدا </strong>(قد تؤثر على 1 من كل 10,000 شخص)<br />صداع دائم ، مع الشعور بالرغبة بالتقيؤ (الغثيان) أو التقيؤ، التغير في بصرك بما في ذلك عدم وضوح الرؤية. قد تكون هذه علامات ارتفاع ضغط الدم الحميد داخل الجمجمة ، خاصة إذا تم أخذ أوراتين مع المضادات الحيوية المسماة تيتراسيكلين.<br /><strong>توقف عن أخذ أوراتين على الفور واتصل بطبيبك.</strong></p><p>&nbsp;</p><p><strong>مشاكل الأمعاء والمعدة<br />تأثيرات نادرة جدا</strong> (قد تؤثر على 1 من كل 10,000 شخص)<br />ألم شديد في البطن ، مع أو بدون إسهال دموي حاد ، والشعور بالغثيان والتقيؤ. يمكن أن تكون هذه علامات دالة على مشاكل هضمية خطيرة.<br /><strong>توقف عن أخذ أوراتين على الفور واتصل بطبيبك.</strong></p><p><br /><strong>اضطرابات العين<br />تأثيرات نادرة جدا</strong> (قد تؤثر على 1 من كل 10,000 شخص)<br />عدم وضوح الرؤية</p><p><br /><strong>إذا كنت تعاني من عدم وضوح الرؤية ، توقف عن تناول أوراتين فورًا واتصل بطبيبك.</strong><br />إذا تأثر بصرك بأي طريقة أخرى أخبر الطبيب بأسرع ما يمكن.</p><p><br /><strong>العظام والعضلات<br />تكرار غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة)</strong><br />ضعف العضلات الذي يمكن أن يكون مهددًا للحياة ، مع مشكلة صعوبة في تحريك الذراعين أو الساقين ، أو وجود مناطق مؤلمة ، أومتورمة ، أو بها كدمات في الجسم ، أو بول داكن اللون ، أو قلة أو عدم خروج البول ، أو اضطراب أو جفاف .هذه علامات على انحلال الربيدات ، وهو انهيار في الأنسجة العضلية يمكن أن يؤدي إلى الفشل الكلوي. قد يحدث هذا إذا كنت تمارس نشاطًا بدنيًا مكثفًا أثناء العلاج بأوراتين.</p><p><br /><strong>أنواع أخرى من التفاعل<br />تأثيرات شائعة جدا </strong>(قد تؤثر على أكثر من 1 من كل 10 أشخاص)<br />جفاف الجلد وخاصة الشفتين والوجه. إلتهاب الجلد، إلتهاب الشفتين ، والطفح الجلدي ، وحكة خفيفة وتقشير طفيف.<br />استخدم كريم مرطب من بداية العلاج .يصبح الجلد أكثر هشاشة وأكثر احمرارًا من المعتاد ، خاصة الوجه .ألم في الظهر؛ ألم في العضلات ؛ آلام المفاصل خاصة عند الأطفال والمراهقين.<br /><strong>لتجنب تفاقم أي مشاكل في العظام أو العضلات </strong>، قلل من النشاط البدني المكثف في حال تناول الأوراتين.</p><p><br />التهاب العين (التهاب الملتحمة) ومنطقة الجفن و جفاف العينين , اسأل الصيدلي عن قطرات العين المناسبة .إذا كان لديك جفاف في العينين وترتدي العدسات اللاصقة ، قد تحتاج إلى ارتداء النظارات بدلا من ذلك. ارتفاع نسبة إنزيمات الكبد في اختبارات الدم .مستويات الدهون المتغيرة في الدم (بما في ذلك HDL أو الدهون الثلاثية.). الكدمات أو النزيف أو التخثر بسهولة أكبر - إذا تأثرت خلايا التخثر.<br />فقر الدم - الضعف ، والدوخة ، وبشرة شاحبة &ndash; إذا تأثرت خلايا الدم الحمراء</p><p><br /><strong>التأثيرات الشائعة</strong> (قد تؤثر على 1 من كل 10 أشخاص)<br />صداع الرأس. مستويات أعلى من الكوليسترول في الدم .البروتين أو الدم في البول.<br />أكثر عرضة للإصابة بالعدوى - إذا تأثرت خلايا الدم البيضاء .داخل الأنف يصبح جاف ويابس، مما يسبب نزيف خفيف في الأنف تقرح أو التهاب الحلق والأنف .ردود فعل تحسسية مثل الطفح ، الحكة.ذا كان لديك أي رد فعل تحسسي،<br />توقف عن أخذ أوراتين والاتصال بطبيبك.</p><p><br /><strong>تأثيرات نادرة </strong>(قد تؤثر على 1 من كل 1000 شخص)<br />تساقط الشعر .هذا عادة ما يكون مؤقتا فقط ، يجب أن يعود شعرك للطبيعي بعد انتهاء العلاج.</p><p><br /><strong>تأثيرات نادرة جدًا</strong> (قد تؤثر على 1 من كل 10,000 شخص)<br />قد لا ترى بشكل جيد في الليل .عمى الألوان ورؤية اللون يزداد سوءا .قد تزيد الحساسية للضوء .قد تجد أنك بحاجة إلى ارتداء النظارات الشمسية لحماية عينيك من أشعة الشمس الساطعة .مشاكل الرؤية الأخرى بما في ذلك ، الرؤية المشوهة ، السطح الغائم على العين )عتامة القرنية ، إعتام عدسة العين(. العطش الشديد؛ حاجة متكررة للتبول، اختبارات الدم تظهر زيادة في نسبة السكر في الدم، هذه يمكن أن تكون كلها علامات مرض السكري. يمكن أن يزداد حب الشباب سوءًا في الأسابيع القليلة الأولى ، لكن الأعراض يجب أن تتحسن بمرور الوقت .التهاب وانتفاخ واسمرار الجلد أكثر من العادة ، خاصة على الوجه .التعرق أو الحكة الزائدة .التهاب المفاصل؛ الاضطرابات العظمية )النمو المتأخر والنمو الإضافي والتغيرات في كثافة العظام( ؛ نمو العظام قد يتوقف .ترسب الكالسيوم في الأنسجة الرخوة ، وآلام الأوتار، ومستويات عالية من انهيار العضلات في الدم إذا كنت تمارس الرياضة بقوة. الالتهابات البكتيرية في قاعدة الظفر، تغير لون الأظافر، التورم ، التفريغ ، القيح. ندبات سميكة بعد الجراحة .زيادة شعر الجسم .التشنجات ، والنعاس ، والدوخة .تورم وانتفاخ الغدد اللمفاوية . جفاف الحلق ، بحة في الصوت ضيق في الصدر ، صعوبات السمع &ndash; شعور بالتعب عموما. مستويات عالية من حمض اليوريك في الدم .الالتهابات البكتيرية. التهاب الأوعية الدموية (في بعض الأحيان مع كدمات ، بقع حمراء)</p><p><br /><strong>تكرار غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة)</strong><br />تحول لون البول إلى لون بني داكن. مشاكل في الانتصاب أو الحفاظ عليه. انخفاض الرغبة الجنسية. تورم الثدي مع أو بدون إيلام عند الذكور. جفاف المهبل. التهاب المفصل العجزي الحرقفي ، وهو نوع من آلام الظهر الالتهابية التي تسبب ألمًا في الأرداف أو أسفل الظهر. التهاب مجرى البول.</p><p><br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا تفاقمت أي من الآثار الجانبية ، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة ، فيرجى إخبار طبيبك أو مقدم الرعاية الصحية أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن نظر و متناول الأطفال.<br />يحفظ أوراتين <strong>10</strong> ملجم في درجة حرارة أقل من <strong>30</strong> درجة مئوية.<br />يحفظ أوراتين <strong>20</strong> ملجم في درجة حرارة أقل من <strong>30</strong> درجة مئوية.</p><p><br />يخزن في الحزمة الأصلية والحفاظ على الشريطة في الكرتون الخارجي من أجل الحماية من الرطوبة والضوء.<br />)EXP( لا تستخدم بعد تاريخ انتهاء الصلاحية&nbsp;<strong>(EXP) </strong>المذكور على العبوة والشريطة.<br /><strong>أعد الكبسولات المتبقية إلى الصيدلي</strong>. احتفظ بها فقط إذا أخبرك طبيبك بذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما يحتويه أوراتين:<br />المادة الفعالة </strong>في أوراتين هو ايزوتريتينوين <strong>10 </strong>ملجم ، ايزوتريتينوين <strong>20</strong> ملجم.<br /><strong>المكونات الأخرى </strong>هي زيت فول الصويا ودل-ألفا-توكوفيرول، ثنائي صوديوم الإديتيت, بوتيل هيدروكسي انيسول ، زيت الصويا المهدرج جزئياً ،زيت نباتي مهدرج ، و شمع العسل الأصفر. هيكل الكبسولة يحتوي على: الجيلاتين ، الجلسرين ، محلول السوربيتول <strong>70</strong> ٪ (غير مبلور)، ثاني أكسيد التيتانيوم والماء النقي. يحتوي أوراتين <strong>10</strong> ملجم أيضاً على&nbsp;أكسيد الحديد الأسود و بونسو <strong>4R</strong>.تحتوي كبسولة أوراتين <strong>20</strong> ملجم أيضًا على بونسو <strong>4R</strong> و انديجو لاكوير.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>شكل و محتويات الأوراتين:<br />كبسولات الأوراتين 10 ملجم </strong>هي لينة ، بيضاوية ، وبنفسجي اللون تحتوي على سائل أصفر / برتقالي.<br /><strong>كبسولات أوراتين 20 ملجم </strong>هي لينة ، بيضاوية ، واللون أحمر مارون تحتوي على سائل أصفر / برتقالي.<br /><strong>تتوفر كبسولات أوراتين بسعة 10 ملجم و 20 ملجم </strong>في عبوات تحتوي على<strong> 30 و 60 </strong>كبسولة .لاتتوفر كل أحجام<br />العبوات في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل إذن التسويق و المصنع:</strong><br />دوغلاس للأدوية المحدودة<br />أوكلاند 0610 ، نيوزيلندا<br />)09( 835- الهاتف: 0660<br />medinfo@douglas.co.nz : البريد الالكتروني</p><p><br /><strong>الصانع</strong><br />سويس كاب أ ج<br />هوسينستراس 35<br />سي إتش- 9533 كيرشبيرج<br />سويسرا</p><p>&nbsp;</p><p><strong>للإبلاغ عن أي من الآثار الجانبية ومشاكل الجودة، يرجى الاتصال بالمركز الوطني للتيقظ و السلامة الدوائية :</strong><br />مركز الاتصال الموحد : 19999<br />npc.drug@sfda.gov.sa : البريد الالكتروني<br />/https://ade.sfda.gov.sa : الموقع الالكتروني<br />*أوراتين هي علامة تجارية مسجلة في نيوزيلند ودولللإبلاغ عن أي من الآثار الجانبية ومشاكل الجودة، يرجى الاتصال بالمركز الوطني للتيقظ و السلامة الدوائية :<br />مركز الاتصال الموحد : 19999<br />npc.drug@sfda.gov.sa : البريد الالكتروني<br />/https://ade.sfda.gov.sa : الموقع الالكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oratane 20 mg soft gelatin capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Oratane 20 mg soft gelatin capsule contains 20 mg of isotretinoin.
Excipients with known effect:
Contains soya-bean products and sorbitol. Sulfur dioxide is present as a residue.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oratane 20 mg capsules: maroon coloured, oval, soft-gelatin capsules containing a yellow/orange opaque viscous liquid.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Severe forms of acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic anti-bacterials and topical therapy.<br />Oratane should not be used to treat prepubertal acne and not in children aged less than 12 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong><br />&nbsp;</p><p>Isotretinoin should only be prescribed by or under the supervision of physicians with expertise in the use of systemic retinoids for the treatment of severe acne and a full understanding of the risks of isotretinoin therapy and monitoring requirements.</p><p><strong>Paediatric Population</strong></p><p>Oratane should not be used for the treatment of prepubertal acne and is not recommended in children less than 12 years of age due to a lack of data on efficacy and safety.</p><p><strong>Adults including adolescents and the elderly</strong>:</p><p>Isotretinoin therapy should be started at a dose of 0.5 mg/kg daily. The therapeutic response to isotretinoin and some of the adverse effects are dose-related and vary between patients. This necessitates individual dosage adjustment during therapy. For most patients, the dose ranges from 0.5-1.0 mg/kg per day.</p><p>Long-term remission and relapse rates are more closely related to the total dose administered than to either duration of treatment or daily dose. It has been shown that no substantial additional benefit is to be expected beyond a cumulative treatment dose of 120-150 mg/kg. The duration of treatment will depend on the individual daily dose. A treatment course of 16-24 weeks is normally sufficient to achieve remission.</p><p>In the majority of patients, complete clearing of the acne is obtained with a single treatment course. In the event of a definite relapse a further course of isotretinoin therapy may be considered using the same daily dose and cumulative treatment dose. As further improvement of the acne can be observed up to 8 weeks after discontinuation of treatment, a further course of treatment should not be considered until at least this period has elapsed.</p><p><strong>Patients with renal impairment</strong></p><p>In patients with severe renal insufficiency treatment should be started at a lower dose (e.g. 10 mg/day). The dose should then be increased up to 1 mg/kg/day or until the patient is receiving the maximum tolerated dose (see section 4.4).</p><p><strong>Patients with intolerance</strong></p><p>In patients who show severe intolerance to the recommended dose, treatment may be continued at a lower dose with the consequences of a longer therapy duration and a higher risk of relapse. In order to achieve the maximum possible efficacy in these patients the dose should normally be continued at the highest tolerated dose.</p><p><u><strong>Method of administration</strong></u></p><p>The capsules should be taken with food once or twice daily<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Isotretinoin is contraindicated in women who are pregnant or breastfeeding (see section 4.6).

Isotretinoin is contraindicated in women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme are met (see section 4.4).

Isotretinoin is also contraindicated in patients with hypersensitivity to isotretinoin or to any of the excipients listed in section 6.1. Oratane capsules contain refined soya-bean oil and partially hydrogenated soya-bean oil. Therefore, Oratane capsules are contraindicated in patients allergic to peanut or soya.

If your doctor has told you that you have intolerance to the sugars fructose or sorbitol

Isotretinoin is also contraindicated in patients
• With hepatic insufficiency
• With excessively elevated blood lipid values
• With hypervitaminosis A
• Receiving concomitant treatment with tetracyclines (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><strong>Teratogenic effects</strong></p><p>Oratane is a powerful human teratogen inducing a high frequency of severe and life-threatening birth defects.<br /><strong>Oratane is strictly contraindicated in:</strong><br />- Pregnant women<br />- Women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme are met</p><p><strong><u>Children and adolescents</u></strong></p><p>The use of Oratane in children under the age of 12 is not recommended. This is because it is not known if it is safe or effective in this age group.</p><p>Oratane should not be used to treat prepubertal acne and not in children aged less than 12 years of age.<br />&nbsp;</p><p><strong><u>Pregnancy Prevention Programme</u></strong></p><p>This medicinal product is TERATOGENIC</p><p>Isotretinoin is contraindicated in women of childbearing potential unless all of the following conditions of the Pregnancy Prevention Programme are met:</p><p>&bull; She has severe acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic anti-bacterials and topical therapy (see section 4.1 &rdquo;Therapeutic indications&ldquo;).</p><p>&bull; The potential for pregnancy must be assessed for all female patients.</p><p>&bull; She understands the teratogenic risk.</p><p>&bull; She understands the need for rigorous follow-up on a monthly basis.</p><p>&bull; She understands and accepts the need for effective contraception, without interruption, 1 month before starting treatment, throughout the entire duration of treatment and for 1 month after the end of treatment. At least one highly effective method of contraception (i.e. a user-independent form) or two complementary user-dependent forms of contraception should be used.</p><p>&bull; Individual circumstances should be evaluated in each case, when choosing the contraception method, involving the patient in the discussion, to guarantee her engagement and compliance with the chosen measures.</p><p>&bull; Even if she has amenorrhea she must follow all of the advice on effective contraception.</p><p>&bull; She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy or if she might be pregnant.</p><p>&bull; She understands the need and accepts to undergo regular pregnancy testing before, ideally monthly during treatment and 1 month after stopping treatment.</p><p>&bull; She has acknowledged that she has understood the hazards and necessary precautions associated with the use of isotretinoin.<br />These conditions also concern women who are not currently sexually active unless the prescriber considers that there are compelling reasons to indicate that there is no risk of pregnancy.<br />The prescriber must ensure that:</p><p>&bull; The patient complies with the conditions for pregnancy prevention as listed above, including confirmation that she has an adequate level of understanding.</p><p>&bull; The patient has acknowledged the aforementioned conditions.</p><p>&bull; The patient understands that she must consistently and correctly use one highly effective method of contraception (i.e. a user-independent form) or two complementary user-dependent forms of contraception, for at least 1 month prior to starting treatment and is continuing to use effective contraception throughout the treatment period and for at least 1 month after cessation of treatment.</p><p>&bull; Negative pregnancy test results have been obtained before, during and 1 month after the end of treatment. The dates and results of pregnancy tests should be documented.</p><p>If pregnancy occurs in a woman treated with isotretinoin, treatment must be stopped and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice.</p><p>If pregnancy occurs after stopping treatment there remains a risk of severe and serious malformation of the foetus. This risk persists until the product has been completely eliminated, which is within one month following the end of treatment.</p><p><u><strong>Contraception</strong></u></p><p>Female patients must be provided with comprehensive information on pregnancy prevention and should be referred for contraceptive advice if they are not using effective contraception. If the prescribing physician is not in a position to provide such information the patient should be referred to the relevant healthcare professional.</p><p>As a minimum requirement, female patients of childbearing potential must use at least one highly effective method of contraception (i.e. a user-independent form), or two complementary user-dependent forms of contraception. Contraception should be used for at least 1 month prior to starting treatment, throughout treatment and continue for at least 1 month after stopping treatment with isotretinoin, even in patients with amenorrhea.</p><p>Individual circumstances should be evaluated in each case, when choosing the contraception method involving the patient in the discussion, to guarantee her engagement and compliance with the chosen measures.</p><p><u><strong>Pregnancy testing</strong></u></p><p>According to local practice, medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL are recommended to be performed, as follows.</p><p><u><strong>Prior to starting therapy:</strong></u></p><p>At least one month after the patient has started using contraception, and shortly (preferably a few days) prior to the first prescription, the patient should undergo a medically supervised pregnancy test. This test should ensure the patient is not pregnant when she starts treatment with isotretinoin.</p><p><u><strong>Follow-up visits</strong></u></p><p>Follow-up visits should be arranged at regular intervals, ideally monthly. The need for repeated medically supervised pregnancy tests every month should be determined according to local practice including consideration of the patient&#39;s sexual activity, recent menstrual history (abnormal menses,<br />missed periods or amenorrhea) and method of contraception. Where indicated, follow-up pregnancy tests should be performed on the day of the prescribing visit or in the 3 days prior to the visit to the prescriber.</p><p><u><strong>End of treatment</strong></u></p><p>One month after stopping treatment, women should undergo a final pregnancy test.</p><p><u><strong>Prescribing and dispensing restrictions</strong></u></p><p>For women of childbearing potential, the prescription duration of Oratane should ideally be limited to 30 days in order to support regular follow up, including pregnancy testing and monitoring. Ideally, pregnancy testing, issuing a prescription and dispensing of Oratane should occur on the same day. Dispensing of isotretinoin should occur within a maximum of 7 days of the prescription.</p><p>This monthly follow-up will allow ensuring that regular pregnancy testing and monitoring is performed and that the patient is not pregnant before receiving the next cycle of medication.</p><p><u><strong>Male patients</strong></u></p><p>The available data suggest that the level of maternal exposure from the semen of the patients receiving Oratane, is not of a sufficient magnitude to be associated with the teratogenic effects of Oratane. Male patients should be reminded that they must not share their medication with anyone, particularly not females.</p><p><u><strong>Additional precautions</strong></u></p><p>Patients should be instructed never to give this medicinal product to another person, and to return any unused capsules to their pharmacist at the end of treatment.</p><p>Patients should not donate blood during therapy and for 1 month following discontinuation of isotretinoin because of the potential risk to the foetus of a pregnant transfusion recipient.</p><p><u><strong>Educational material</strong></u></p><p>In order to assist prescribers, pharmacists and patients in avoiding foetal exposure to isotretinoin the Marketing Authorisation Holder will provide educational material to reinforce the warnings about the teratogenicity of isotretinoin, to provide advice on contraception before therapy is started and to provide guidance on the need for pregnancy testing.</p><p>Full patient information about the teratogenic risk and the strict pregnancy prevention measures as specified in the Pregnancy Prevention Programme should be given by the physician to all patients, both male and female.</p><p><u><strong>Psychiatric disorders</strong></u></p><p>Depression, depression aggravated, anxiety, aggressive tendencies, mood alterations, psychotic symptoms, and very rarely, suicidal ideation, suicide attempts and suicide have been reported in patients treated with isotretinoin (see section 4.8). Particular care needs to be taken in patients with a history of depression and all patients should be monitored for signs of depression and referred for appropriate treatment if necessary. However, discontinuation of isotretinoin may be insufficient to alleviate symptoms and therefore further psychiatric or psychological evaluation may be necessary.</p><p>Awareness by family or friends may be useful to detect mental health deterioration.</p><p><u><strong>Skin and subcutaneous tissues disorders</strong></u></p><p>Acute exacerbation of acne is occasionally seen during the initial period but this subsides with continued treatment, usually within 7-10 days, and usually does not require dose adjustment.</p><p>Exposure to intense sunlight or to UV rays should be avoided. Where necessary a sun-protection product with a high protection factor of at least SPF 15 should be used.</p><p>Aggressive chemical dermabrasion and cutaneous laser treatment should be avoided in patients on isotretinoin for a period of 5-6 months after the end of the treatment because of the risk of hypertrophic scarring in atypical areas and more rarely post inflammatory hyper or hypopigmentation in treated areas. Wax depilation should be avoided in patients on isotretinoin for at least a period of 6 months after treatment because of the risk of epidermal stripping.</p><p>Concurrent administration of isotretinoin with topical keratolytic or exfoliative anti-acne agents should be avoided as local irritation may increase (see section 4.5).</p><p>Patients should be advised to use a skin moisturising ointment or cream and a lip balm from the start of treatment as isotretinoin is likely to cause dryness of the skin and lips.</p><p>There have been post-marketing reports of severe skin reactions (e.g. erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)) associated with isotretinoin use. As these events may be difficult to distinguish from other skin reactions that may occur (see section 4.8), patients should be advised of the signs and symptoms and monitored closely for severe skin reactions. If a severe skin reaction is suspected, isotretinoin treatment should be discontinued.</p><p><u><strong>Allergic reactions</strong></u></p><p>Anaphylactic reactions have been rarely reported, in some cases after previous topical exposure to retinoids. Allergic cutaneous reactions are reported infrequently. Serious cases of allergic vasculitis, often with purpura (bruises and red patches) of the extremities and extracutaneous involvement have been reported. Severe allergic reactions necessitate interruption of therapy and careful monitoring.</p><p><u><strong>Eye disorders</strong></u></p><p>Dry eyes, corneal opacities, decreased night vision and keratitis usually resolve after discontinuation of therapy. Cases of dry eyes not resolving after discontinuation of therapy have been reported. Dry eyes can be helped by the application of a lubricating eye ointment or by the application of tear replacement therapy. Intolerance to contact lenses may occur which may necessitate the patient to wear glasses during treatment.</p><p>Decreased night vision has also been reported and the onset in some patients was sudden (see section 4.7). Patients experiencing visual difficulties should be referred for an expert ophthalmological opinion. Withdrawal of isotretinoin may be necessary.</p><p><u><strong>Musculo-skeletal and connective tissue disorders</strong></u></p><p>Myalgia, arthralgia and increased serum creatine phosphokinase values have been reported in patients receiving isotretinoin, particularly in those undertaking vigorous physical activity (see section 4.8). In some cases, this may progress to potentially life-threatening rhabdomyolysis.</p><p>Bone changes including premature epiphyseal closure, hyperostosis, and calcification of tendons and ligaments have occurred after several years of administration at very high doses for treating disorders of keratinisation. The dose levels, duration of treatment and total cumulative dose in these patients generally far exceeded those recommended for the treatment of acne.</p><p>Sacroiliitis has been reported in patients exposed to isotretinoin. To differentiate sacroiliitis from other causes of back pain, in patients with clinical signs of sacroiliitis, further evaluation may be needed including imaging modalities such as MRI. In cases reported post-marketing, sacroiliitis improved after discontinuation of Oratane and appropriate treatment.</p><p><u><strong>Benign intracranial hypertension</strong></u></p><p>Cases of benign intracranial hypertension have been reported, some of which involved concomitant use of tetracyclines (see section 4.3 and section 4.5). Signs and symptoms of benign intracranial hypertension include headache, nausea and vomiting, visual disturbances and papilloedema. Patients who develop benign intracranial hypertension should discontinue isotretinoin immediately.</p><p><u><strong>Hepatobiliary disorders</strong></u></p><p>Liver enzymes should be checked before treatment, 1 month after the start of treatment, and subsequently at 3 monthly intervals unless more frequent monitoring is clinically indicated. Transient and reversible increases in liver transaminases have been reported. In many cases these changes have been within the normal range and values have returned to baseline levels during treatment. However, in the event of persistent clinically relevant elevation of transaminase levels, reduction of the dose or discontinuation of treatment should be considered.</p><p><u><strong>Renal insufficiency</strong></u></p><p>Renal insufficiency and renal failure do not affect the pharmacokinetics of isotretinoin. Therefore, isotretinoin can be given to patients with renal insufficiency. However, it is recommended that patients are started on a low dose and titrated up to the maximum tolerated dose (see section 4.2).</p><p><u><strong>Lipid Metabolism</strong></u></p><p>Serum lipids (fasting values) should be checked before treatment, 1 month after the start of treatment, and subsequently at 3 monthly intervals unless more frequent monitoring is clinically indicated. Elevated serum lipid values usually return to normal on reduction of the dose or discontinuation of treatment and may also respond to dietary measures.</p><p>Isotretinoin has been associated with an increase in plasma triglyceride levels. Isotretinoin should be discontinued if hypertriglyceridaemia cannot be controlled at an acceptable level or if symptoms of pancreatitis occur (see section 4.8). Levels in excess of 800 mg/dL or 9 mmol/L are sometimes associated with acute pancreatitis, which may be fatal.</p><p><u><strong>Gastrointestinal disorders</strong></u></p><p>Isotretinoin has been associated with inflammatory bowel disease (including regional ileitis) in patients without a prior history of intestinal disorders. Patients experiencing severe (haemorrhagic) diarrhoea should discontinue isotretinoin immediately.</p><p><u><strong>High Risk Patients</strong></u></p><p>In patients with diabetes, obesity, alcoholism or a lipid metabolism disorder undergoing treatment with isotretinoin, more frequent checks of serum values for lipids and/or blood glucose may be necessary. Elevated fasting blood sugars have been reported, and new cases of diabetes have been diagnosed during isotretinoin therapy.</p><p><u><strong>Excipients</strong></u></p><p>This medicinal product contains 24.26 mg sorbitol in each 20 mg capsule.</p><p>The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.</p><p>The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should not take vitamin A as concurrent medication due to the risk of developing hypervitaminosis A.</p><p>Cases of benign intracranial hypertension (pseudotumor cerebri) have been reported with concomitant use of isotretinoin and tetracyclines. Therefore, concomitant treatment with tetracyclines must be avoided (see section 4.3 and section 4.4).</p><p>Concurrent administration of isotretinoin with topical keratolytic or exfoliative anti-acne agents should be avoided as local irritation may increase (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p><br /><strong>Pregnancy is an absolute contraindication to treatment with isotretinoin (see section 4.3). Women of childbearing potential have to use effective contraception during and up to one month after treatment. If pregnancy does occur in spite of these precautions during treatment with Oratane or in the month following, there is a great risk of very severe and serious malformation of the foetus.</strong><br />&nbsp;</p><p>The foetal malformations associated with exposure to isotretinoin include central nervous system abnormalities (hydrocephalus, cerebellar malformation/abnormalities, microcephaly), facial dysmorphia, cleft palate, external ear abnormalities (absence of external ear, small or absent external auditory canals), eye abnormalities (microphthalmia), cardiovascular abnormalities (conotruncal malformations such as tetralogy of Fallot, transposition of great vessels, septal defects), thymus gland abnormality and parathyroid gland abnormalities. There is also an increased incidence of spontaneous abortion.</p><p>If pregnancy occurs in a woman treated with isotretinoin, treatment must be stopped and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice.</p><p><u><strong>Breastfeeding</strong></u></p><p>Isotretinoin is highly lipophilic, therefore the passage of isotretinoin into human milk is very likely. Due to the potential for adverse effects in the child exposed via mothers&#39; milk, Oratane is contraindicated during breast-feeding (see section 4.3).<br />&nbsp;</p><p><u><strong>Fertility</strong></u></p><p>Isotretinoin, in therapeutic dosages, does not affect the number, motility and morphology of sperm and does not jeopardise the formation and development of the embryo on the part of the men taking isotretinoin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oratane could potentially have an influence on the ability to drive and use machines.</p><p>A number of cases of decreased night vision have occurred during isotretinoin therapy and in rare instances have persisted after therapy (see section 4.4 and section 4.8). Because the onset in some patients was sudden, patients should be advised of this potential problem and warned to be cautious when driving or operating machines.</p><p>Drowsiness, dizziness and visual disturbances have been reported very rarely. Patients should be warned that if they experience these effects, they should not drive, operate machinery or take part in any other activities where the symptoms could put either themselves or others at risk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Summary of safety profile</strong></u></p><p>Some of the side effects associated with the use of isotretinoin are dose-related. The side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. The following symptoms are the most commonly reported undesirable effects with isotretinoin: dryness of the skin, dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis) and the eyes (conjunctivitis).</p><p><u><strong>Tabulated list of adverse reactions</strong></u></p><p>The incidence of the adverse reactions calculated from pooled clinical trial data involving 824 patients and from post-marketing data are presented in the table below. The adverse reactions are listed below by MedDRA system organ class (SOC) and categories of frequency. Frequency categories are defined as Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping and SOC, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>Table 1 Tabulated list of adverse reactions in patients treated with isotretinoin</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:1098px"><tbody><tr><td style="width:184px"><strong>System Organ Class</strong></td><td style="width:180px"><strong>Very Common</strong></td><td style="width:178px"><strong>Common</strong></td><td style="width:185px"><strong>Rare</strong></td><td style="width:182px"><strong>Very Rare</strong></td><td style="width:183px"><strong>Not known*</strong></td></tr><tr><td style="width:184px"><strong>Infections</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Gram positive (mucocutaneous) bacterial infection</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Blood and lymphatic system disorders</strong></td><td style="width:180px">Thrombo-cytopenia, anaemia, thrombocytosis, red blood cell sedimentation rate increased</td><td style="width:178px">Neutropenia</td><td style="width:185px">&nbsp;</td><td style="width:182px">Lymphadenopathy</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Immune system disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">Anaphylactic reactions, hypersensitivity, allergic skin&nbsp;reaction</td><td style="width:182px">&nbsp;</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Metabolism and nutrition disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Diabetes mellitus, hyperuricaemia</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Psychiatric disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">Depression, depression aggravated, aggressive tendencies, anxiety, mood alterations.</td><td style="width:182px">Suicide, suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Nervous system disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">Headache</td><td style="width:185px">&nbsp;</td><td style="width:182px">Benign intracranial hypertension, convulsions, drowsiness, dizziness</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Eye disorders</strong></td><td style="width:180px">Blepharitis, conjunctivitis, dry eye, eye irritation</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Papilloedema (as sign of benign intracranial hypertension), cataract, colour blindness (colour vision deficiencies), contact lens intolerance, corneal opacity, decreased night vision, keratitis, photophobia, visual disturbances, blurred vision.</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Ear and labyrinth disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Hearing impaired</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Vascular disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Vasculitis (for example Wegener&#39;s granulomatosis, allergic vasculitis)</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Respiratory, thoracic and mediastinal disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">Nasopharyngitis, epistaxis, nasal dryness</td><td style="width:185px">&nbsp;</td><td style="width:182px">Bronchospasm (particularly in patients with asthma), hoarseness</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Gastrointestinal disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Inflammatory bowel disease, colitis, ileitis, pancreatitis, gastrointestinal haemorrhage,haemorrhagic diarrhoea, nausea dry throat (see section 4.4)</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Hepatobiliary disorders</strong></td><td style="width:180px">Transaminase increased (see section 4.4)</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Hepatitis</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px"><strong>Skin and subcutaneous tissues disorders</strong></td><td style="width:180px">Pruritus, rash erythematous, dermatitis, cheilitis, dry skin, localised exfoliation, skin fragility (risk of frictional trauma)</td><td style="width:178px">&nbsp;</td><td style="width:185px">Alopecia</td><td style="width:182px">Acne fulminans, acne aggravated (acne flare), erythema (facial), exanthema, hair disorders, hirsutism, nail dystrophy, paronychia, photosensitivity reaction, pyogenic granuloma, skin hyperpigmentation, sweating increased</td><td style="width:183px">Erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis</td></tr><tr><td style="width:184px"><strong>Musculo-skeletal and connective tissue disorders</strong></td><td style="width:180px">Arthralgia, myalgia, back pain (particularly in children and adolescent patients)</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Arthritis, calcinosis (calcification of ligaments and tendons), epiphyses premature fusion, exostosis, (hyperostosis), reduced bone density, tendonitis</td><td style="width:183px">Rhabdomyolysis sacroiliitis</td></tr><tr><td style="width:184px"><strong>Renal and urinary disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Glomerulonephritis</td><td style="width:183px">Urethritis</td></tr><tr><td style="width:184px"><strong>Reproductive system and breast disorders</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">&nbsp;</td><td style="width:183px">Sexual dysfunction including erectile dysfunction and decreased libido, gynaecomastia, Vulvovaginal dryness</td></tr><tr><td style="width:184px"><strong>General disorders and administration&nbsp;site conditions</strong></td><td style="width:180px">&nbsp;</td><td style="width:178px">&nbsp;</td><td style="width:185px">&nbsp;</td><td style="width:182px">Granulation tissue (increased formation of), malaise</td><td style="width:183px">&nbsp;</td></tr><tr><td style="width:184px">I<strong>nvestigations</strong></td><td style="width:180px">Blood triglycerides increased, high density lipoprotein decreased</td><td style="width:178px">Blood cholesterol increased, blood glucose increased, haematuria, proteinuria</td><td style="width:185px">&nbsp;</td><td style="width:182px">Blood creatine phosphokinase increased</td><td style="width:183px">&nbsp;</td></tr></tbody></table><p><strong>* cannot be estimated from the available data</strong><br />&nbsp;</p><p><strong><u>To report any side effect(s):</u></strong><br />&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>&nbsp;</p><p><strong>&bull; The National Pharmacovigilance Centre (NPC)</strong><br />&nbsp;</p><p><strong>- SFDA Call Center: 19999<br />- Email: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isotretinoin is a derivative of vitamin A. Although the acute toxicity of isotretinoin is low, signs of hypervitaminosis A could appear in cases of accidental overdose. Manifestations of acute vitamin A toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. Signs and symptoms of accidental or deliberate overdosage with isotretinoin would probably be similar. These symptoms would be expected to be reversible and to subside without the need for treatment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Retinoid for treatment of acne, ATC code: D10B A01</p><p dir="ltr"><u><strong>Mechanism of action</strong></u></p><p dir="ltr">Isotretinoin is a stereoisomer of all-trans retinoic acid (tretinoin). The exact mechanism of action of isotretinoin has not yet been elucidated in detail, but it has been established that the improvement observed in the clinical picture of severe acne is associated with suppression of sebaceous gland activity and a histologically demonstrated reduction in the size of the sebaceous glands. Furthermore, a dermal anti-inflammatory effect of isotretinoin has been established.</p><p dir="ltr"><u><strong>Clinical efficacy and safety</strong></u></p><p dir="ltr">Hypercornification of the epithelial lining of the pilosebaceous unit leads to shedding of corneocytes into the duct and blockage by keratin and excess sebum. This is followed by formation of a comedone and, eventually, inflammatory lesions. Isotretinoin inhibits proliferation of sebocytes and appears to act in acne by re-setting the orderly program of differentiation. Sebum is a major substrate for the growth of Propionibacterium acnes so that reduced sebum production inhibits bacterial colonisation of the duct.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />The absorption of isotretinoin from the gastro-intestinal tract is variable and dose-linear over the therapeutic range. The absolute bioavailability of isotretinoin has not been determined, since the compound is not available as an intravenous preparation for human use, but extrapolation from dog studies would suggest a fairly low and variable systemic bioavailability. When isotretinoin is taken with food, the bioavailability is doubled relative to fasting conditions.<br />&nbsp;</p><p><strong><u>Distribution</u></strong><br />Isotretinoin is extensively bound to plasma proteins, mainly albumin (99.9 %). The volume of distribution of isotretinoin in man has not been determined since isotretinoin is not available as an intravenous preparation for human use. In humans little information is available on the distribution of isotretinoin into tissue. Concentrations of isotretinoin in the epidermis are only half of those in serum. Plasma concentrations of isotretinoin are about 1.7 times those of whole blood due to poor penetration of isotretinoin into red blood cells.</p><p><u><strong>Biotransformation</strong></u><br />After oral administration of isotretinoin, three major metabolites have been identified in plasma: 4-oxo-isotretinoin, tretinoin, (all-trans retinoic acid), and 4-oxo-tretinoin. These metabolites have shown biological activity in several in vitro tests. 4-oxo-isotretinoin has been shown in a clinical study to be a significant contributor to the activity of isotretinoin (reduction in sebum excretion rate despite no effect on plasma levels of isotretinoin and tretinoin). Other minor metabolites include glucuronide conjugates. The major metabolite is 4-oxo-isotretinoin with plasma concentrations at steady state, that are 2.5 times higher than those of the parent compound.</p><p>Isotretinoin and tretinoin (all-trans retinoic acid) are reversibly metabolised (interconverted), and the metabolism of tretinoin is therefore linked with that of isotretinoin. It has been estimated that 20-30 % of an isotretinoin dose is metabolised by isomerisation.</p><p>Enterohepatic circulation may play a significant role in the pharmacokinetics of isotretinoin in man. In vitro metabolism studies have demonstrated that several CYP enzymes are involved in the metabolism of isotretinoin to 4-oxo-isotretinoin and tretinoin. No single isoform appears to have a predominant role. Isotretinoin and its metabolites do not significantly affect CYP activity.</p><p><u><strong>Elimination</strong></u><br />After oral administration of radiolabelled isotretinoin approximately equal fractions of the dose were recovered in urine and faeces. Following oral administration of isotretinoin, the terminal elimination half-life of unchanged drug in patients with acne has a mean value of 19 hours. The terminal elimination half-life of 4-oxo-isotretinoin is longer, with a mean value of 29 hours.</p><p>Isotretinoin is a physiological retinoid and endogenous retinoid concentrations are reached within approximately two weeks following the end of isotretinoin therapy.</p><p><u><strong>Hepatic impairment</strong></u><br />Since isotretinoin is contraindicated in patients with hepatic impairment, limited information on the kinetics of isotretinoin is available in this patient population.</p><p><u><strong>Renal impairment</strong></u><br />Renal failure does not significantly reduce the plasma clearance of isotretinoin or 4-oxo-isotretinoin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Acute toxicity</u></strong><br />The acute oral toxicity of isotretinoin was determined in various animal species. LD50 is approximately 2000 mg/kg in rabbits, approximately 3000 mg/kg in mice, and over 4000 mg/kg in rats.</p><p><strong><u>Chronic toxicity</u></strong><br />A long-term study in rats over 2 years (isotretinoin dosage 2, 8 and 32 mg/kg/d) produced evidence of partial hair loss and elevated plasma triglycerides in the higher dose groups. The side effect spectrum of isotretinoin in the rodent thus closely resembles that of vitamin A, but does not include the massive tissue and organ calcifications observed with vitamin A in the rat. The liver cell changes observed with vitamin A did not occur with isotretinoin.</p><p>All observed side effects of hypervitaminosis A syndrome were spontaneously reversible after withdrawal of isotretinoin. Even experimental animals in a poor general state had largely recovered within 1&ndash;2 weeks.<br />&nbsp;</p><p><u><strong>Teratogenicity</strong></u><br />Like other vitamin A derivatives, isotretinoin has been shown in animal experiments to be teratogenic and embryotoxic.</p><p>Due to the teratogenic potential of isotretinoin there are therapeutic consequences for the administration to women of a childbearing age (see section 4.3, section 4.4, and section 4.6).</p><p><strong><u>Mutagenicity</u></strong><br />Isotretinoin has not been shown to be mutagenic in in vitro or in vivo animal tests.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Capsule filling:</strong></u></p><p>Soya-bean oil, All-rac-alpha-tocopherol, disodium edetate, butylated hydroxyanisole, partially hydrogenated soya-bean oil, hydrogenated vegetable oil and yellow beeswax.</p><p><u><strong>Capsule shells contain:</strong></u></p><p>Gelatin, glycerol, sorbitol solution 70% (non-crystallising), titanium dioxide, and purified water.<br />Oratane 20 mg also contains ponceau 4R and indigotine lacquer.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Not applicable.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Store below 30 &deg;C.</strong></p><p><strong>Store in the original package and keep blister in the outer carton in order to protect from moisture and light.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>(PVC/PVDC) aluminium blister packs containing 30 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Any unused medicine or waste should be disposed of in accordance with local requirements.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Douglas Pharmaceuticals Ltd
Central Park Drive, Lincoln,
Auckland 0610
New Zealand
Ph: (09) 835 0660
Email: medinfo@douglas.co.nz
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date of first Authorisation: 13 May 2018

9. DATE OF THE REVISION OF THE TEXT
01 June 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>